BioNTech SE

General information
BioNTech SE
An der Goldgrube 12
55131 Mainz, Rhineland-Palatinate
Germany

Contact person: Ugur Sahin, Chief Executive Officer & Co-Founder
Company main phone: +49 (6131) 90840
Company main fax:  +49 (6131) 90842121
Website:  https://biontech.de
Year founded:2008
Source of foundation:Spin-off from university
Name of foundation source:Johannes Gutenberg University Mainz
No. of employees: Worldwide:  7807
Corporate description / mission:
BioNTech SE develops and commercializes immunotherapies to treat cancer and infectious diseases. The company's product BNT116 is an mRNA cancer immunotherapy candidate encoding a fixed set of six non-mutated antigens that were identified to be frequently expressed in non-small cell lung cancer (“NSCLC”). The company's another product BNT211 is an autologous tumor-specific CAR-T cell therapy candidate targeting CLDN6 which is enhanced by a CAR-T cell amplifying RNA cancer vaccine (CARVac) that is based on BioNTech’s FixVac platform and encodes the CAR-T target antigen CLDN6.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2019
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Antibody-drug-conjugate
  • Cell therapy
  • Immunotherapy
  • Nucleic acid drugs
  • Small molecules
  • Vaccines
Primary therapeutic areas:
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
Business model:
  • Manufacturer
  • Service company
  • Supplier / Distributor
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:2
Phase I:7
Phase II:42
Phase III:9
On the market:1
Description of products:
Autogene cevumeran (BNT122/RO7198457)
BNT325/DB-1305
Trastuzumab pamirtecan (BNT323/DB-1303) etc
Technology used:
mRNA-based Platforms
Protein-based Platforms
Cell Therapy-based Platforms
Small Molecule-based Platforms
Financing details
Fiscal year (end of) 2025
Revenues:USD 3'229.67M
R&D expenses:USD 2'368.77M
Cash:USD 8'988.67M
No. of shares:252'884'261
Market cap. / valuation:USD 22'274.05M
Collaborations & Clients
Partnering strategy / collaborations:
Autolus Therapeutics
Bill & Melinda Gates Foundation
Biotheus
Coalition for Epidemic Preparedness Innovations (CEPI)
Crescendo Biologics
Duality Biologics
Fosun Pharma, etc.
© 2026 Biotechgate by Venture Valuation
X